Olanzapine LA-Risperidone

Olanzapine
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Olanzapine
EMEA zypadhera
PubChem 4585
PubMed Olanzapine
Kompas (Dutch) Olanzapine
Wikipedia Olanzapine
Risperidone
Type antipsychotic
Group atypical AP
Other use moodstabilizer
links
ATC-code N05AX08
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Drugs.com risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone

Switch medication from Olanzapine_LA to Risperidone.

Nietinrijdenbord.png Stop Olanzapine_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Risperidone
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[4]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Olanzapine_LA
Eenrichtingbord.png — Risperidone


  1. ↑ 1.01.1 KNMP; Informatorium Medicamentorum 2015; Monografie "risperidon" (Dutch)
  2. ↑ Woods SW; Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
  3. ↑ 3.03.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  4. ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.